Pediatric Clinical Trials Market Companies
- Synteract
- ICON Plc.
- Syneos Health
- Medpace, Inc
- PPD Inc.
- Premier Research
- LabCorp Drug Development
- QPS Holding
- Pfizer Inc.
- The Emmes Company, LLC
- IQVIA Inc.
Recent News:
- UCLA just began a breakthrough clinical trial for a vaccination that targets severe childhood brain tumors. UCLA Health Jonsson Comprehensive Cancer Center researchers have launched a first-of-its-kind clinical trial to assess the safety and efficacy of a cancer vaccine targeting H3 G34-mutant diffuse hemispheric glioma, a highly aggressive brain tumor that typically affects adolescents and young adults. This type of brain tumor is identified by a unique mutation in the H3-3A gene, which encodes a key regulatory component of histone H3. This mutation causes serious anomalies in RNA processing, with far-reaching implications for cancer behavior and treatment response. The UCLA-developed vaccine is intended to target the genetic abnormalities found in these tumor types.
- The SickKids project, which will begin in February 2024, will pave the way for clinical trials of children uncommon diseases. Researchers at The Hospital for Sick Children (SickKids) devised an innovative way to address the difficulties involved with conducting randomized clinical trials in children with rare diseases. In a study published in Hepatology, a team of SickKids scientists developed an innovative and robust statistical approach that could eliminate the need for traditional randomized clinical trials by demonstrating the efficacy of a medication in reducing disease progression and liver transplants in children with Alagille syndrome.
- The OUtMATCH Clinical Trial drug was authorized by the FDA in February 2024 to minimize allergy responses induced by inadvertent food exposure. The Food and Drug Administration has approved omalizumab to treat allergic responses, including anaphylaxis, that can develop following unintended exposure to one or more foods in adults and children aged one year and older who have food allergies. The FDA granted authorization based on data from a scheduled intermediate evaluation of the Phase 3 NIAID research. Patients receiving omalizumab should continue to avoid foods to which they are allergic. Omalizumab has not been approved for emergency treatment of allergic reactions, including anaphylaxis.